chufangao/CTO huggingface dataset:
Clinical trial NCT03538691: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1149.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-07-13
Primary completion date: 2022-07-08
Completion date: 2022-07-29
Baseline population: Enrolled Sample included all participants who signed the informed consent form and entered Phase A.
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Clinical trial NCT04145037: Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
Official title: The Guard1 Trial, an Open-Label, Multinational Phase 1/2 Study of the Safety and Efficacy of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 for Subjects With Type 1 Gaucher Disease
Sponsor: AVROBIO (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: This study was voluntarily terminated by the sponsor to halt development and was not based on any safety or medical reasons.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-30
Primary completion date: 2023-08-21
Completion date: 2023-08-21
Baseline population: Treatment-naïve arm did not enroll any subjects at the time of study termination.
Limitations and caveats: GCase PBL results were not available at many timepoints due to sample instability. CFB in chitotriosidase was calculated for only 2 subjects because timepoints for the other 2 subjects exceeded ULOQ of the assay and could not be quantified. BMA samples were collected and batched for VCN analysis, but due to study termination, they were not analyzed and thus discarded. Change from baseline BMD scores were not able to be evaluated for some subjects due to missing baseline and/or Week 52 data.
Plan to share individual participant data: NO
Clinical trial NCT04412837: The Use of Cannabinoid Patch for Knee Osteoarthritis
Official title: The Use of Cannabinoid Patch for Knee Osteoarthritis
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Inadequate funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-31
Primary completion date: 2023-12-31
Completion date: 2024-02-29
Plan to share individual participant data: NO
Clinical trial NCT04930562: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
Official title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of BN101 in Subject With Chronic Graft Versus Host Disease (cGVHD) After at Least Fist Line of Systemic Therapy
Sponsor: BioNova Pharmaceuticals (Shanghai) LTD. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-27
Primary completion date: 2022-06-10
Completion date: 2022-12-10
Clinical trial NCT04326868: Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon
Official title: Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon
Acronym: BenziR
Sponsor: Centre de Recherche Médicale de Lambaréné (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 255.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-11-11
Primary completion date: 2020-12-31
Completion date: 2021-01-30
Plan to share individual participant data: YES
IPD sharing description: The Data will be shared in RedCap database.
IPD time frame: The date will be available around December 2020 until september 2021.
IPD access criteria: The Data will be shared12 months after study completion in research journal. A lle the result will be publicly available the
Clinical trial NCT03258008: Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
Official title: Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Closed the trial for infeasibility due to slow accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-04
Primary completion date: 2021-11-05
Completion date: 2021-11-05
Baseline population: All participants who signed the consent are included in the baseline characteristics.
Clinical trial NCT05399290: Subantimicrobial Doxycycline in Acne
Official title: A Randomized Controlled Trial Investigating the Pediatric Patient Experience of Subantimicrobial Dose Doxycycline for Acne Treatment
Sponsor: Michigan State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-19
Primary completion date: 2021-11-08
Completion date: 2021-11-08
Clinical trial NCT04075136: Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
Official title: OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: IRB stopped study due to safety concerns before any participants were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-03-30
Primary completion date: 2024-11-30
Completion date: 2024-12-31
Plan to share individual participant data: NO
IPD sharing description: Results will updated once final analysis is complete.
Clinical trial NCT03104270: Combination Study for High Risk Multiple Myeloma Patients
Official title: A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Sponsor: Oncotherapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early by Funding Sponsor due to low enrollment.
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-13
Primary completion date: 2019-10-25
Completion date: 2020-01-23
Plan to share individual participant data: NO
Clinical trial NCT02061293: A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
Official title: A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-06-30
Primary completion date: 2021-07-30
Completion date: 2021-07-30
Clinical trial NCT04052425: Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
Official title: Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 330.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-09-20
Primary completion date: 2021-03-18
Completion date: 2021-10-21
Baseline population: Baseline data are reported for members of the Safety Population, comprised of all participants who applied ruxolitinib cream or vehicle cream at least once. Treatment groups for this population were determined according to the actual treatment the participant applied on Day 1.
Plan to share individual participant data: NO
Clinical trial NCT03993314: Optimizing Anesthesia for Post Partum Tubal Ligations
Official title: Comparing 1% Spinal Chloroprocaine to Low-dose Bupivacaine Using the Epidural Volume Extension Technique for Post-Partum Tubal Ligation
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of recruitment due to COVID-19 pandemic; chloroprocaine shortage
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-13
Primary completion date: 2020-12-03
Completion date: 2020-12-03
Plan to share individual participant data: NO
Clinical trial NCT03933397: Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
Official title: A Comparison of Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
Acronym: COMPARE-VOE
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to COVID enrollment numbers needed to meet the primary endpoint will not be met.
Enrollment: 328.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-13
Primary completion date: 2022-05-13
Completion date: 2022-05-20
Baseline population: Participants arrived at the emergency department and once determined that they were not COVID + and were there for a vaso-occlusive episode and bed placement occurred, baseline data were collected. Baseline data were not collected on 8 participants following bed placement. 1 withdrew consent, 2 were investigator decision, 3 confirmed COVID + and 1 did not provide baseline information.
Plan to share individual participant data: NO
Clinical trial NCT05528913: Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)
Official title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study With a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (Anti-IL5Rα) in Adult Patients With Chronic Prurigo
Sponsor: Charite University, Berlin, Germany (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Financing has been withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-31
Primary completion date: 2023-10-19
Completion date: 2023-10-19
Plan to share individual participant data: NO
Clinical trial NCT05932979: Effect of the Administration of L-arginine vs. Placebo in Patients Diagnosed With Presbyvestibulopathy.
Official title: Effect of the Administration of L-arginine vs. Placebo on the vHIT Result, Vestibular Caloric Tests and Symptoms of Patients Diagnosed With Presbyvestibulopathy.
Acronym: L-ARGPRES
Sponsor: Centro Universitario de Tonalá (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: the investigation was cancelled because there was no monetary resource to complete it.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-02
Primary completion date: 2023-11-01
Completion date: 2023-12-30
Plan to share individual participant data: NO
Clinical trial NCT04183634: An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.
Official title: An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.
Sponsor: Sandoz (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company Decision
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-03
Primary completion date: 2020-03-16
Completion date: 2020-03-16
Plan to share individual participant data: NO
Clinical trial NCT03049735: LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Official title: LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Sponsor: Myovant Sciences GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 388.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-04-26
Primary completion date: 2019-04-29
Completion date: 2020-08-24
Baseline population: All participants who were enrolled and randomized in the study.
Limitations and caveats: None reported
Plan to share individual participant data: NO
Clinical trial NCT03970330: Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis
Official title: A Randomized Double-Blind Placebo-Controlled Trial to Assess the Effectiveness of Low-Dose Naltrexone in Combination With Standard Treatment in Women With Chronic Pelvic Pain Secondary to Endometriosis
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Original PI left institution, lack of funding to continue
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-16
Primary completion date: 2021-06-21
Completion date: 2021-06-21
Plan to share individual participant data: YES
IPD sharing description: Participant data will be shared that underlie the results reported in this article, after deidentification. Documents that will be available are the study protocol, statistical analysis plan, informed consent. Analyses is to achieve the study aims in the approved proposal.
IPD time frame: Data will be available one year after publication according to PMCID journal guidelines.
IPD access criteria: Data will plan to be published in a peer-reviewed journal and /or posted at clinicaltrials.gov websites or other websites per request of the NIH. Materials will also be accessible through email contact of Primary Investigator.
Clinical trial NCT02328287: Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion
Official title: A Pilot Phase 2a, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Rescue Interbody Fusion
Sponsor: Bone Therapeutics S.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-09-30
Primary completion date: 2018-04-30
Completion date: 2020-04-30
Clinical trial NCT04195958: A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
Official title: A Multicenter, Open-Label, Single-Arm Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma
Acronym: EDURO
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Due to low enrollment, this study was terminated early.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-30
Primary completion date: 2021-10-18
Completion date: 2021-10-18
Baseline population: This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.
Limitations and caveats: This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on this, there were not enough participants enrolled to perform a meaningful analysis.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).~For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02677896: A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Official title: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Acronym: ARCHES
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1150.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-03-09
Primary completion date: 2018-10-14
Completion date: 2024-07-31
Baseline population: All Randomized Participants
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT04481191: Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)
Official title: A Phase 3 Randomized, Open-Label, Clinical Trial to Study the Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of V260 and Inactivated Poliomyelitis Vaccine (IPV) in Chinese Healthy Infants
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 400.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-25
Primary completion date: 2021-05-08
Completion date: 2021-05-08
Limitations and caveats: Protocol Amendment 3 was issued after study completion. The purpose of the amendment was to update the Sponsor entity name and address.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04233034: Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
Official title: Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer)
Acronym: CLVer
Sponsor: Jaeb Center for Health Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 113.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-07-09
Primary completion date: 2022-09-15
Completion date: 2022-09-30
Clinical trial NCT04665310: Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
Official title: Evaluation of Early Dose Escalation Using Extended-Release Tacrolimus (Envarsus XR®) to Reduce Acute Rejection and Donor Specific Antibodies in African American Renal Transplant Recipients
Sponsor: The Methodist Hospital Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study not started, funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-09-01
Primary completion date: 2020-10-31
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT02992886: Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly
Official title: Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly
Sponsor: ChineseAMS (UNKNOWN)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-30
Primary completion date: 2021-05-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT04853368: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
Official title: A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Strategic considerations
Enrollment: 48.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-20
Primary completion date: 2023-06-05
Completion date: 2023-06-05
Baseline population: The Full Analysis Set (FAS) includes all enrolled subjects (randomized subjects for Cohort 2) who received at least 1 dose of study drug as dual or triple combination (or corresponding placebo). The FAS was used for demographics and baseline characteristics analyses.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03708926: Effect of Abaloparatide on Lumbar Disc Degeneration
Official title: Effect of Abaloparatide on Lumbar Disc Degeneration
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Inability to obtain drugs from supplier.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-31
Primary completion date: 2023-08-31
Completion date: 2024-02-29
Plan to share individual participant data: NO